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2014; Chen et al., 2015), the authors for the ﬁrst time conﬁrmed the
same role in GC, correlating high levels of PAK6 with a poor OS and a
poor DFS. This knowledge could be useful for the development of
novel targeted therapies aiming to speciﬁcally target PAK6, or its
down-stream pathway. Also the exact molecular oncological function
of PAK6 in GC deserves further attention in the context of precisionGastric cancer (GC) is the 4th most common human malignant dis-
ease and the second-leading cancer-related deaths in the world(De
Manzoni et al., 2016). Treatment with 5-ﬂuorouracil/oxaliplatin (5-
FU/oxaliplatin) chemotherapy has proven to signiﬁcantly improve sur-
vival of patients with metastatic GC(Lordick et al., 2014).
In EBioMedicine, Jiang et al. in two large cohorts of stage II and III GC
patients sought to investigate the correlation among high levels of ser-
ine/threonine p21-activated kinase 6 (PAK6) with survival rates and
chemosensitivity to 5-FU/oxaliplatin(Jiang et al., 2017). High PAK6 ex-
pression correlated with poor prognosis in chemotherapy treated GCs,
but it did not show any association in non-chemotherapy treated GCs.
Moreover high PAK6 increased chemosensitivity to 5-FU/oxaliplatin.
After the determination of the predictive values of six biomarkers
(PAK6, TS, ERCC1, Cox2, Ki-67 and p21WAF1) the authors constructed a
support vector machine (SVM) classiﬁer.With the help of this classiﬁer,
a subgroup in the stage II and III GC patients was identiﬁed that could
easily beneﬁt from the 5-FU/oxaliplatin chemotherapy. In fact, the che-
motherapywas able to signiﬁcantly improve disease free survival (DFS)
and overall survival (OS) in the high chemotherapy score – CS-SVM
classiﬁer; p = 0.004, p = 0.001 respectively, but it did not in the low
CS-SVM (p = 0.562, p = 0.761) in the validation cohort. Based on the
CS-SVM classiﬁer results, a nomogramwas developed to create a quan-
titative method for the clinical prediction of stage II and III GC patients'
probability of OS over a 3- and 5-years period of time.
Two merits for the Jiang et al. study should be commended. Al-
though data from literature proved that the highly expressed levels ofom.2017.06.028.
Department of Oncology, San
ana.it (G. Roviello).
.V. This is an open access article undPAK6 correlate with poor prognosis in several tumors(Chen et al.,
medicine development.
The second commendation to the work goes for the development of
the CS-SVMmethod to predictwhich subgroup of GC responds better to
the chemotherapy. This method, if proven useful in multicentre clinical
settings, could become a valuable tool to introduce in the clinics to help
determining those patients that could respond better to chemotherapy.
Moreover, discovery of additional biomarkers could become crucial
in improving this tool to predict GC chemotherapy responders. Deter-
mining the relative role of other recognized GC biomarkers could en-
hance the accuracy of the method. With new and always more
advanced technologies, such as the triple quadrupole LC-MS/MS with
MRM analysis, the discovery of more biomarkers and the determination
of their prognostic values could bring to an always more accurate prog-
nostic tool for chemotherapy responders in GC.
In conclusion, there is the need to improve results of chemotherapy
in GC(Petrioli et al., 2015; Roviello et al., 2016),the CS-SVM represents a
good method to predict a subgroup of stage II and III GC patients that
could better respond to the chemotherapy and determine through a no-
mogram the probability of patients OS at 3 or 5 years. The discovery of
more GC biomarkers in this context could improve the method that if
validated in multicentre clinical settings could become a valuable tool
to introduce in the clinics, in order to help in the decision-making for
taking this type of chemotherapy that could be beneﬁcial in GC patients.
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